Company intelligence / Profile preview

Lodo Therapeutics

New York, New York, United States
Ownership
Private
Development stage
Other
01

Overview

Lodo Therapeutics developed a proprietary genomics and AI-driven platform to mine microbial DNA for structurally diverse natural products, aiming to address previously undruggable targets for infectious disease, immunology, and oncology. It was acquired preclinical, with public output focused on platform demonstrations and strategic partnerships, rather than clinical results[1][2][4].

Therapeutic areas
Infectious DiseasesOncologyImmunology
Modalities
Small molecule
Industry
Biotech
02

Partnerships

The Rockefeller University[1]Bill & Melinda Gates Foundation[1][2]ARCH Venture Partners[2]AbbVie Ventures[2]Alexandria Venture Investments[2]

Beyond the preview

Go deeper on Lodo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lodo Therapeutics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call